Seletracetam is a small-molecule SV2A modulator used in epilepsy research; it decreases seizure activity in various epilepsy models; it reduces synaptic responses in a time-, frequency-, and concentration-dependent manner; it modulates presynaptic release rates; it inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro.